Consultant in General Paediatrics and Vaccinology, Honorary Senior Clinical Lecturer, Group Head / PI, Consultant Physician and Member of congregation
Dr Matthew Snape, MBBS FRCPCH MD, is a Consultant in General Paediatrics and Vaccinology at the NIHR Oxford Biomedical Research Council and the Children’s Hospital Oxford, Oxford University Hospitals NHS Trust. He is also an Honorary Senior Clinical Lecturer at the Department of Paediatrics, University of Oxford, a Jenner Investigator and a fellow of St Cross College, Oxford.
Dr Snape's principal areas of research relate to vaccines against meningococcal, pneumococcal, and influenza, and prevention of disease through maternal immunisation. In 2014/2015 he was the lead investigator on a 'first in human' phase 1 study of a candidate ebola vaccine, providing data crucial to the planning of subsequent studies in West Africa.
Dr Snape graduated from the University of Melbourne in 1993 and completed his basic paediatric training at the Royal Children’s Hospital, Melbourne before continuing his training at St Mary’s Hospital, London. While working in the Paediatric Intensive Care Unit at St Mary’s hospital he became interested in the prevention of invasive meningococcal disease by immunisation, and on completion of his clinical training took up a post as a research fellow (later Clinical Lecturer) at the Oxford Vaccine Group, University of Oxford. While here he completed his post- graduate Doctor of Medicine (MD) degree, awarded by the University of Melbourne in 2009. He has been employed as a Consultant in Geenza and ebola disease, and prevention of disease through maternal immunisation.
Dr Snape was acknowledged as an NIHR Clinical Research Network ‘Leading Commercial Principal Investigator’ in 2015 by Dame Sally Davis, Chief Medical Office, and has published over 70 manuscripts relating to immunisation. He is also a member of the Meningitis Research Foundation's Medical Advisory Group.
Dr Snape is an Academic Training Programme Director for Oxford University Clinical Academic Graduate School (OUCAGS), with a particular focus on paediatric academic training.
Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection.
McGinley JP. et al, (2022), The Journal of infectious diseases
Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.
Ratcliffe H. et al, (2022), Archives of disease in childhood
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.
Carr JP. et al, (2022), Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
Rollier CS. et al, (2022), Vaccine
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), The Lancet. Respiratory medicine